Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Infect Dis
Principais autores: Udwadia, Zarir F., Barkate, Hanmant, Patil, Saiprasad, Rangwala, Shabbir, Wu, Wen, Caracta, Cynthia F., Tandon, Monika
Formato: Artigo
Idioma:Inglês
Publicado em: GLENMARK PHARMACEUTICALS LIMITED. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Assuntos:
Letter to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8012082/
https://ncbi.nlm.nih.gov/pubmed/33601032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2021.02.028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados